AbbVie touts Rinvoq win in giant cell arteritis, potentially teeing up another label expansion

[cafead]

via On Thursday, AbbVie said that Rinvoq, also known as upadacitinib, met its primary endpoint in the SELECT-GCA trial in patients with giant cell arteritis (GCA). Specifically, 46% of patients treated with the AbbVie drug at the 15 mg dose—plus a 26-week steroid taper regimen—achieved sustained remission from week 12 through week 52.

article source